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Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin
that exerts its cytotoxic activity by inhibiting a nuclear enzyme
topoisomerase (Topo) I as a novel therapeutic target (Hsiang and
Liu, 1988). CPT-11 has demonstrated a remarkable anti-tumour
activity for both small-cell lung cancer (SCLC) and non-small-cell
lung cancer (NSCLC) in phase II trials (Fukuoka et al, 1992;
Masuda et al, 1992a). Cisplatin (CDDP), a recent key drug for
treatment of lung cancer (Bonomi, 1996), has a different mecha-
nism of action, and its overlapping toxicity with CPT-11 is
minimal. Because CDDP was reported to show synergism with
CPT-11 (Kudoh et al, 1993), this combination was considered to
be evaluated. A phase I study of this combination for NSCLC, in
which a fixed dose of CDDP (80 mg m–2) given on day 1 was
combined with an escalating dose of CPT-11 (30–70 mg m–2) on
days 1, 8 and 15, was reported (Masuda et al, 1992b, 1993). The
maximally tolerated dose (MTD) and the recommended dose for a
phase II study of CPT-11 were determined to be 70 mg m–2 and
60 mg m–2 respectively. In this study, a high response rate (54%)
was achieved, but leucopenia and diarrhoea were dose-limiting
toxicities and made further dose escalation of CPT-11 difficult
(Masuda et al, 1992b, 1993). A phase II study conducted with this
dose and schedule showed objective response rates of 48% for
NSCLC (Nakagawa et al, 1993) and 78% for SCLC (Fujiwara et
al, 1994). Then the following dose-escalation trial was conducted
by combining recombinant human granulocyte colony-stimulating
factor (rhG-CSF) with the original regimen. The dose of CPT-11
could be increased up to 80 mg m–2 (a 33% increase above the
original regimen). However, diarrhoea, a dose-limiting toxicity of
CPT-11, prevented further dose escalation and the objective
response rate remained at 50% (Masuda et al, 1994).
The present study was planned to investigate whether the frac-
tionated administration of both CDDP and CPT-11 on days 1 and 8
could attenuate dose-limiting toxicities and improve the treatment
outcome compared with the previous trial. The primary objective
of this study was to determine the MTD of CPT-11 in combination
with a fixed dose of CDDP. The other objectives included evalua-
tion of the therapeutic activity and determination of the dose-
limiting toxicity of this regimen.
MATERIALS AND METHODS
Patient selection
Eligibility requirements for entry into the study were as follows:
(1) histologically or cytologically proven lung cancer; (2) no prior
chemotherapy, radiotherapy or surgery; (3) age of 75 years or less;
(4) clinical stage of IIIA with bulky N2, IIIB or IV for NSCLC, or
extensive disease (ED) for SCLC; (5) performance status (PS) of
0–2 on the Eastern Cooperative Oncology Group (ECOG) scale
(Oken et al, 1982); (6) the presence of measurable or evaluable
disease; (7) adequate functions of the kidney (creatinine clearance
³ 60 ml min–1), liver (ALT, AST < twice the upper limit of
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normal), and bone marrow (a leucocyte count ³ 4000 ml–1 and a
platelet count ³ 100 000 ml–1); (8) no concomitant malignancies;
and (9) a written form of informed consent.
Evaluation
Staging procedures included complete history and physical
examination, a complete blood cell count (CBC), standard blood
chemistry profile, 24-h urine creatinine clearance, ECG, a chest
radiograph, fibreoptic bronchoscopy, computerized tomographic
(CT) scans of the chest and abdomen, magnetic resonance imaging
of the brain, and radionuclide bone scan.
The CBC was repeated two or three times a week, and blood
chemistry, 24-h urine creatine clearance, urinalysis, and chest
radiograph were repeated at least once a week after initial evalua-
tion. CT scans of the chest were repeated once a treatment cycle.
After the completion of chemotherapy, each patient was restaged
with all the tests used during the initial work-up.
Treatment plan
Both CDDP and CPT-11 were given by 1-h intravenous infusion
with an infusion pump on days 1 and 8. The dose of CDDP was
fixed at 60 mg m–2 and given with 100 ml of physiological saline.
Ondansetron (4 mg) or granisetron (3 mg) was administered intra-
venously just before CDDP administration. CPT-11 dissolved in
300 ml of physiological saline was given after the administration of
CDDP. After administration of CDDP and CPT-11, hydration
consisting of 3000 ml of physiological saline was given. The
starting dose of CPT-11 was 40 mg m–2 and the dose was increased
by 10 mg m–2 for dose escalation. At least three patients were
enrolled at each dose level. If all three patients developed the signif-
icant toxicity, which was defined as grade 4 haematological toxicity
or grade 3 non-haematological toxicity except nausea or vomiting,
the dose level was determined to be the MTD. If two of the three
patients encountered the significant toxicity, as many as six patients
in total were subjected to the same dose level. When the significant
toxicity developed in more than half of the patients, the dose was
also determined to be the MTD. Toxicity and response were evalu-
ated according to the criteria of ECOG (Oken et al, 1982). Time to
progression and overall survival were defined as the time from
beginning of chemotherapy until first documentation of disease
progression and to death respectively. No intrapatient dose escala-
tion was performed. The treatment was repeated every 4 weeks up to
four cycles unless the disease progression occurred. If grade 4
haematolological toxicity or grade 3 non-haematological toxicity
such as diarrhoea was observed in the previous course, the dose of
CPT-11 was reduced by 10 mg m–2 in the next cycle. The dose of
CDDP was reduced by 10 mg m–2 for development of grade 4
haematological toxicity or by 30 mg m–2 for development of grade 3
renal toxicity. Before the next course was started, leucocyte and
platelet counts had to be at least 3500 ml–1 or more and 100 000 ml–1
or more respectively.
Pharmacokinetics
A heparinized blood sample (5 ml) was obtained from the cubital
vein opposite to the injection site at 12 points as follows: before and
15 and 30 min after the start of CPT-11 infusion, at the end of infu-
sion, and 15 and 30 min, and 1, 2, 4, 8, 11 and 23 h after infusion.
The blood was centrifuged immediately, and the plasma was stored
at –20°C until analysis. Plasma levels of CPT-11 and SN-38 were
Table 1 Patient characteristics
Dose of
No. Age Sex Histology Stage PS CPT-11
1 64 Male Adeno IV 2 40
2 57 Female Adeno IV 0 40
3 66 Male Adeno IV 1 40
4 62 Male Squamous IIIB 0 50
5 57 Male Squamous IV 0 50
6 66 Male Largea IIIB 1 50
7 69 Male Small ED(IV) 0 60
8 71 Male Adeno IIIA 1 60
9 67 Male Squamous IIIA 1 60
10 46 Male Adeno IV 1 70
11 38 Male Large IV 1 70
12 70 Female Small ED(IIIB) 0 70
13 47 Female Squamous IV 0 60
14 62 Male Adeno IV 1 60
15 65 Male Adeno IIIB 1 60
16 50 Male Small ED(IV) 1 60
17 49 Male Adenosquamous IIIB 0 60
18 62 Male Small ED(IIIB) 1 60
19 52 Male Small ED(IIIB) 0 60
20 65 Male Adeno IV 0 60
21 48 Male Adeno IV 0 50
22 61 Male Small ED(IV) 0 50
23 71 Male Squamous IV 0 50
24 57 Male Squamous IIIB 0 50
aThe diagnosis was altered to thymic carcinoma at autopsy.
Table 2 Dose escalation schedule
Dose Dose (mg m–2) of No. of patients No. of courses
level
CPT-11 CDDP Enrolled With toxicitya
administered
14 0 6 0 3 0 8
25 0 6 0 3 0 1 1
36 0 6 0 3 1 1 1
47 0 6 0 3 2 6
56 0 6 0 8 5 1 8
65 0 6 0 4 0 1 1
a Grade 4 haematological or grade 3 or 4 non-haematological toxicity on ECOG grade except nausea and vomiting.986 H Ueoka et al
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determined by high-performance liquid chromatography (HPLC)
as described previously (Kaneda et al, 1990). Pharmacokinetic
parameters on each day were compared using the paired two-tailed
Student’s t-test.
RESULTS
Determination of MTD
Between November 1994 and August 1995, 24 patients were allo-
cated in this study. One patient was evaluated only for toxicity
because his disease was proven to be thymic carcinoma at autopsy,
though this case was initially diagnosed as large-cell carcinoma of
the lung. Characteristics of all patients are listed in Table 1. The
median age was 62 years ranging from 38 to 71. There were 21 men
and three women. Seventeen patients were diagnosed as NSCLC
and six as SCLC. Dose escalation was conducted as shown in Table
2. Up to a dose level of 50 mg m–2 of CPT-11, no patient developed
the significant toxicity. At a dose level of 60 mg m–2, one patient
developed grade 3 diarrhoea. At a dose level of 70 mg m–2, two
patients developed grade 4 diarrhoea, and one of them also experi-
enced grade 4 leucopenia and thrombocytopenia. This patient died
of sepsis and subsequent multiorgan failure on day 22 of the treat-
ment. Because this dose level was determined to be intolerable, we
treated eight additional patients with CPT-11 at a dose of
60 mg m–2. Among those, five patients developed significant toxic-
ities, which included grade 3 or 4 diarrhoea in three patients, and
grade 4 paralytic ileus, grade 3 hepatic toxicity, grade 3 skin rash
and grade 4 thrombocytopenia each in one patient. Thus, six
patients among a total of 11 patients developed significant toxicity
when treated with 60 mg m–2 of CPT-11. Therefore, the dose level
of 60 mg m–2 of CPT-11 was determined to be the MTD, and the
recommended dose of CPT-11 for a phase II study was considered
to be 50 mg m–2. Then an additional four patients were treated at
this recommended dose level of CPT-11 to confirm its safety. No
severe toxicity was experienced at this dose level.
Toxicity
Haematological toxicity was generally mild. Analysis of the first
course of chemotherapy is shown in Table 3. At the first two dose
levels (40 mg m–2 and 50 mg m–2 of CPT-11), no grade 4 haemato-
logical toxicity was experienced. Only grade 3 leucopenia was
observed in two out of three (67%) and two out of seven patients
(29%) at dose levels of 40 mg m–2 and 50 mg m–2 respectively. At
the dose level of 60 mg m–2, four patients developed grade 3
leucopenia. Of those, one patient developed grade 4 thrombo-
cytopenia which continued for 13 days, and grade 3 thrombo-
cytopenia and grade 3 anaemia were observed in one patient each.
At the highest dose level (70 mg m–2 of CPT-11), one patient
developed grade 4 leucopenia and thrombocytopenia, and an addi-
tional patient developed grade 3 leucopenia. In most cases, the
nadir of leucopenia or thrombocytopenia was observed around day
21, between day 14 and 29, with recovery of a leucocyte count to
³ 4000 ml–1 or a platelet count to ³ 100 000 ml–1 by at latest day 28.
Non-haematological toxicity is summarized in Table 4. The
most prominent and dose-limiting toxicity was diarrhoea. At the
first two dose levels, there was no severe diarrhoea. At dose levels
of 60 mg m–2 and 70 mg m–2 of CPT-11, grade 3 or 4 diarrhoea was
observed in 4 out of 11 (36%) and two out of three (67%) of the
patients respectively. The severe diarrhoea occurred within 2
weeks (range, day 4–13) after the administration of CPT-11, which
was usually controlled with loperamide hydrochloride. However,
it took about 10 days (range, 8–23 days) to recover from the diar-
rhoea. One patient treated with 60 mg m–2 of CPT-11 encountered
grade 4 ileus, which developed at day 12 and continued for 16
days. Grade 3 skin rash occurred in one patient each at the dose
levels of 60 mg m–2 and 70 mg m–2 of CPT-11. The skin rash was
Table 3 Haematological toxicities
Dose of CPT-11 (mg m–2)
40 50 60 70
No. of patients 3 7 11 3
Leucocyte count
Nadir (´103 ml–1) 1.7 (1.5–2.0) 2.9 (1.0–3.8) 3.0 (1.1–3.5) 1.9 (0.2–2.2)
Days to nadir 24 (20–28) 21 (14–27) 19 (15–24) 26 (17–29)
Days to recovery 10 (6–16) 4 (3–17) 5 (2–8) 11 (10–12)
No. of patients with
ECOG grade 3/4 toxicity 2/0 2/0 4/0 1/1
Platelet count
Nadir (´103 ml–1) 112 (90–249) 86 (56–172) 100 (50–181) 103 (2–109)
Days to nadir 24 (22–26) 19 (18–25) 20 (15–23) 21 (20–26)
Days to recovery 10 (7–12) 5 (3–6) 8 (4–13) 6
No. of patients with
ECOG grade 3/4 toxicity 0/0 0/0 1/1 0/1
Haemoglobin level
Nadir (mg dl–1) 9.4 (9.0–9.9) 9.3 (9.2–12.0) 9.4 (8.5–12.4) 9.8 (8.8–11.2)
Days to nadir 30 (26–31) 22 (21–30) 23 (17–29) 26 (29–26)
No. of patients with
ECOG grade 3/4 toxicity 0/0 0/0 1/0 0/0
Data are expressed as a median value (range).Phase I study of irinotecan and cisplatin for lung cancer 987
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transient and effectively treated with intravenous dexamethasone.
Grade 3 hepatotoxicity occurred in one patient, which developed
at day 7 and normalized until day 15. Nausea, vomiting, alopecia
and peripheral neuropathy were also observed, but all of them
were grade 1 or 2, transient and well tolerated. There was no
evidence of severe pulmonary, cardiac or renal toxicity.
Response
Clinical responses were evaluated in 17 patients with NSCLC and
four patients with SCLC (Table 5). An objective response was
observed even at the first level of CPT-11 (40 mg m–2) and there
was no clear relationship between the dose level of CPT-11 and the
response. Although no complete response was achieved, partial
response rates were 76% for NSCLC and 100% for SCLC. Median
time to progression and median survival in four patients with
SCLC were 9.34 (95% confidence interval (95% CI) 7.69–10.98)
months and 16.83 (95% CI 12.55–21.12) months respectively.
Those in 17 patients with NSCLC were 7.33 (95% CI 6.66–8.00)
months and 10.72 (95% CI 8.45–12.99) months respectively.
Pharmacokinetics
The pharmacokinetic parameters of CPT-11 and SN-38 on day 1
and day 8 are summarized in Table 6. Time courses of CPT-11 and
SN-38 concentrations in plasma according to the dose of CPT-11
are shown in Figure 1 and Figure 2 respectively. The plasma
concentrations of CPT-11 and SN-38 reached their maximum
levels just before the end of CPT-11 infusion. Pharmacokinetic
parameters at day 1 and day 8 compared by paired t-test were not
significantly different. The mean beta-half lives of CPT-11 and
SN-38 were 7.56 ± 0.65 h and 9.89 ± 0.95 h respectively. The Cmax
and AUC of CPT-11 were increased along with the dose escalation
of CPT-11 administration. However, those of SN-38 were not
significantly different among different doses of CPT-11 of
40 mg m–2, 50 mg m–2 and 60 mg m–2. One patient, who was
treated with the highest dose (70 mg m–2) and died of severe toxic-
ities, showed markedly high levels of both Cmax (27.3 ng ml–1 on
day 1, 39.5 ng ml–1 on day 8) and AUC (223.4 ng h ml–1 on day 1,
273.0 ng h ml–1 on day 8) of SN-38.
Dose intensity
Dose intensity in cumulative courses are shown in Table 7. Median
number of courses repeated were three and the reasons for drug
discontinuation were as follows: no response (no further therapy in
five patients and change to radiotherapy in four); change to high-
dose chemotherapy as late intensification in three; change to adju-
vant surgery in two; and life-threatening toxicity in two. Up to the
second dose level, more than half of the patients completed four
courses and received greater than 95% of the intended dose.
DISCUSSION
We planned the present study to improve the treatment outcome of
lung cancer by utilizing the synergistic effect between CDDP and
CPT-11 maximally. So we fractionated the administration of both
drugs on days 1 and 8 equally, and repeated at 4-week intervals.
Objective response rates obtained with this regimen were 76% for
NSCLC and 100% for SCLC. These results were considerably
Table 4 Non-haematological toxicities
Dose of CPT-11 (mg m–2)
40 50 60 70
No. of patients 3 7 11 3
Diarrhoea
Grade 1 1 2 6 1
20 2 1 0
30 0 3 0
40 0 1 2
Constipation
Grade 4 0 0 1 0
Nausea and Vomiting
Grade 1 2 5 7 0
21 0 4 3
Alopecia
Grade 1 2 6 7 1
20 0 4 1
Skin rash
Grade 3 0 0 1 1
Liver damage
Grade 3 0 0 1 0
Peripheral neuropathy
Grade 1 0 0 0 1
No. of patients with ECOG
grade 3 or 4 toxicity 0 0 6 2
Table 5 Responses
Dose of CPT-11 (mg m–2)
40 50 60 70 Total
Non-small-cell lung cancer
No. of evaluable patients 3 5 7 2 17
No. of PR (%) 1 (33) 5 (100) 6 (86) 1 (50) 13 (76)
Small-cell lung cancer
No. of evaluable patients 0 1 3 0 4
No. of PR (%) 1 (100) 3 (100) 4 (100)
PR, partial response.988 H Ueoka et al
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better than those of the previous reports (Masuda et al, 1992b,
1993, 1994; Nakagawa et al, 1993; Fujiwara et al, 1994).
As a possible explanation for these favourable results, we
considered synergistic effect between CDDP and CPT-11, high
dose intensity of CDDP and sequence of CDDP/CPT-11 adminis-
tration. In the present study, the synergistic effect between CDDP
and CPT-11 might be intensified compared with the previous trials
because these drugs were simultaneously given for 2 days within
one course.
We fixed the dose of CDDP at 60 mg m–2 because we could
safely give that dose of CDDP with etoposide at 200 mg m–2 in the
previous trials for SCLC (Ohnoshi et al, 1993). This regimen
resulted in the increase of CDDP dose intensity (30 mg m–2
week–1) compared with the previous trials in which CDDP dose
intensity was 20 mg m–2 week–1 (Masuda et al, 1992b, 1993, 1994;
Nakagawa et al, 1993; Fujiwara et al, 1994). In contrast, the dose-
intensity of CPT-11 (25 mg m–2 week–1) in the recommended dose
of this regimen was much less than the dose intensity (45 mg m–2
week–1 without G-CSF or 60 mg m–2 week–1 with G-CSF) in the
previous studies (Masuda et al, 1992b; 1993, 1994; Nakagawa et
al, 1993; Fujiwara et al, 1994). Gralla et al (1981) and Gandara et
al (1989) reported a better response rate in patients treated with
Table 6 Pharmacokinetic parameters of CPT-11 and SN-38
Dose of CPT-11 (mg m–2)
40 50 60 70
Day 1
No. of patients 2 3 8 2
CPT-11
Cmax (mg ml–1) 0.70 ± 0.09 0.90 ± 0.25 0.83 ± 0.07 1.11 ± 0.02
Tmax (h) 0.75 ± 0.25 1.13 ± 0.13 0.88 ± 0.08 1.13 ± 0.13
AUC (mg · h ml–1) 3.03 ± 0.19 4.71 ± 0.16 4.17 ± 0.29 4.45 ± 0.22
MRT (h) 7.96 ± 0.52 7.58 ± 0.70 7.62 ± 0.21 6.99 ± 0.58
SN-38
Cmax (ng ml–1) 11.3 ± 0.2 12.1 ± 1.9 13.0 ± 1.5 19.7 ± 7.6
Tmax (h) 1.25 ± 0.0 1.38 ± 0.13 1.20 ± 0.1 2.00 ± 1.0
AUC (ng · h ml–1) 126.7 ± 4.0 149.1 ± 7.3 121.4 ± 11.8 172.2 ± 51.2
MRT (h) 9.81 ± 0.14 9.95 ± 0.55 10.0 ± 0.4 9.42 ± 0.69
Day 8
No. of patients 2 1 4 2
CPT-11
Cmax (mg ml–1) 0.56 ± 0.09 0.67 0.99 ± 0.12 1.52 ± 0.07
Tmax (h) 1.13 ± 0.13 1.00 0.94 ± 0.16 1.00 ± 0.00
AUC (mg · h ml–1) 3.17 ± 0.18 4.17 4.17 ± 0.33 6.14 ± 1.15
MRT (h) 8.03 ± 0.41 8.19 7.44 ± 0.16 6.56 ± 0.44
SN-38
Cmax (ng ml–1) 12.3 ± 1.3 10.0 13.5 ± 1.2 29.2 ± 10.4
Tmax (h) 1.50 ± 0.0 1.50 1.60 ± 0.2 2.00 ± 1.0
AUC (ng · h ml–1) 154.4 ± 8.2 143.2 139.1 ± 16.8 225.5 ± 47.6
MRT (h) 9.82 ± 0.36 10.74 9.10 ± 0.6 9.07 ± 1.35
Data are expressed as means ± s.d.
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higher doses of CDDP than in those treated with a lower dose,
although Gandara’s subsequent report showed that the higher dose
of CDDP was harmful rather than helpful (Gandara et al, 1993).
Accordingly, the increased dose intensity of CDDP may be one of
the reasons for the high response rate in this study.
As for the sequence of CPT-11 and CDDP, Masuda et al (1992b)
gave CPT-11 first on the basis of their in vitro study (Kudoh et al,
1993). However, we gave CDDP before administration of CPT-11
because this sequence was better than the inverted sequence in our
in vitro study (Aoe et al, 1997). Several mechanisms are under
consideration for this phenomenon. Firstly, CPT-11 may interfere
with a process involved in DNA repair and enhance its cytotoxi-
city when given after administration of a DNA-damaging agent
such as CDDP. Secondly, CDDP administration before CPT-11
may influence the excretion of SN-38. In fact, the patient who
was treated with 70 mg m–2 of CPT-11 showed higher Cmax
(27.3 ng ml–1 on day 1 and 39.5 ng ml–1 on day 8) and equivalent
AUC (172 ng h ml–1 on day 1 and 225 ng h ml–1 on day 8) than
Cmax (13.23 ng ml–1) and AUC (216.0 ng h ml–1) in the previous
trial using a higher dose (80 mg m–2) of CPT-11 (Masuda et al,
1993). Similarly, in the phase I trial of combination chemotherapy
with CDDP and topotecan, the sequence of CDDP before
topotecan was also recommended for the subsequent trials, though
this sequence induced more myelosuppression than the alternate
sequence (Rowinsky et al, 1996).
Haematological toxicity in this study was generally mild and
doses of CPT-11 less than 70 mg m–2 were well tolerated.
However, neither incidence nor severity of diarrhoea was
improved in the present study compared with those in the previous
studies, though the dose intensity of CPT-11, a main agent respon-
sible for diarrhoea, was markedly low. These results strongly
suggest the pharmacokinetic interaction between CDDP and CPT-
11. A synergistic reaction between CDDP and CPT-11 in the
bowel mucosa may be one of the major causes of severe diarrhoea.
Marked interpatient variability in development of toxicity is a
well-known feature of CPT-11 (Fukuoka et al, 1992; Masuda et al,
1992). CPT-11 is transformed to SN-38, an active metabolite of
CPT-11, by carboxylesterase, mainly in the liver, bowel mucosa
and tumour tissue (Kaneda et al, 1990). Then, most of SN-38 is
excreted in the bile as a glucuronate conjugate (Tsuji et al, 1991).
Variability in transformation of CPT-11 to SN-38 or excretion of
SN-38 may be the main cause of interpatient variability of toxicity.
Treatment-related death occurred in a patient who was treated with
70 mg m–2 of CPT-11. This patient showed a considerably high
level of SN-38 in plasma. She was fully eligible for the entry
criteria (ALT 41, AST 41), but her serum was positive for hepatitis
C virus (HCV). Accordingly, in patients with latent hepatic
dysfunction or HCV infection such as this case, SN-38 may be
accumulated in plasma because of the impaired hepatic excreting
ability of SN-38. In the following trials, careful examination of
hepatic function may be necessary to exclude patients with latent
hepatic damage. In this study, dose escalation was performed even
if one of three patients experienced dose-limiting toxicities. This
may have led to the very severe toxicity at the highest dose level.
In conclusion, a combination chemotherapy of CPT-11 and
CDDP in this fractionating dosing schedule is feasible and highly
effective for lung cancer. In seven patients who received the
recommended dose for a phase II study (50 mg m–2 of CPT-11), no
patients encountered severe toxicity and all patients achieved
objective responses. To confirm these encouraging results, a phase
II study of CPT-11 (50 mg m–2) and CDDP (60 mg m–2) in the
present regimen is warranted.
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